Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITYÂŽ coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source
No articles found.
Mirati Therapeutics (NASDAQ: MRTX) is a San Diego-based clinical-stage biotechnolo...
Mirati Therapeutics (NASDAQ: MRTX) is a San Die...
Akero aims to develop and deliver transformational medicines to patients with high...
Akero aims to develop and deliver transformatio...
Love Goodly is on a mission to help women love their bodiesâŚ.and feel good about...
Love Goodly is on a mission to help women love ...
We are a global, high-growth diagnostics company committed to improving patient ca...
We are a global, high-growth diagnostics compan...
The recognized global leader in neuromodulation devices to treat blindness, the co...
The recognized global leader in neuromodulation...
RTI Surgical Holdings, Inc. is a leading global surgical implant company providing...
RTI Surgical Holdings, Inc. is a leading global...
Surface Oncology is an immuno-oncology company on a mission to break through and d...
Surface Oncology is an immuno-oncology company ...
Sorrentoâs lead programs with short-term milestones consist of two clinical stag...
Sorrentoâs lead programs with short-term mile...
SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused...
SELLAS Life Sciences Group, Inc. is a late-stag...
Progenics develops innovative medicines and other technologies to target and treat...
Progenics develops innovative medicines and oth...
Join the National Investor Network and get the latest information with your interests in mind.